Core Viewpoint - Meinian Health (002044) announced that neither the company nor its subsidiaries have experienced overdue guarantees, legal disputes related to guarantees, or losses due to judgments against them [1] Group 1 - The company confirmed the absence of overdue guarantees [1] - There are no ongoing legal disputes involving guarantees [1] - The company has not been subject to any judgments resulting in financial losses related to guarantees [1]

Core Insights - The core viewpoint of the articles highlights the strong financial performance and growth potential of Meinian Health, driven by its AI technology and health management services [1][2]. Financial Performance - In the first three quarters of 2025, Meinian Health reported a net profit of 51.86 million yuan, a year-on-year increase of 110.53% [1]. - The net profit for the third quarter alone was 273 million yuan, reflecting a 13.65% increase compared to the same period last year [1]. - Revenue generated from AI-driven services reached approximately 250 million yuan, marking a 71.02% increase year-on-year [1]. Business Strategy - The company is focusing on enhancing revenue and customer engagement, particularly during the peak health check-up season in the third quarter [1]. - Meinian Health aims to implement cost reduction and efficiency improvement measures while maintaining a diverse revenue stream and high-quality service experience [1]. - The strategy includes a continuous cycle of "professional examination - in-depth service - scientific customization - continuous repurchase" to support high-quality business development [1]. AI and Innovation - According to research from Founder Securities, Meinian Health's AI strategy is entering a harvest phase, with innovative AI products contributing significantly to revenue and profit margins [2]. - The company possesses over 200 million structured health data points, providing a natural advantage in AI product development and iteration [2]. - The integration of AI products is expected to enhance customer value and drive revenue growth in the long term [2].

Core Viewpoint - Meinian Health, a leader in the "AI + health management" sector, reported significant growth in both core profits and AI business in its Q3 2025 financial results, indicating a dual explosion in performance [1][2] Financial Performance - The company achieved a net profit of 51.86 million yuan in the first three quarters, a year-on-year increase of 110.53% [1] - In Q3 alone, the net profit reached 273 million yuan, reflecting a 13.65% growth compared to the same period last year [1] - Revenue generated from AI-driven services amounted to approximately 250 million yuan, marking a 71.02% increase year-on-year [1] Business Strategy - Meinian Health is focusing on enhancing revenue and customer engagement, particularly during the peak health check season in Q3 [1] - The company aims to implement cost reduction and efficiency improvement measures while maintaining a diverse revenue stream [1] - The strategy emphasizes a positive cycle of "professional examination - in-depth service - scientific customization - continuous repurchase" to support high-quality business development [1] AI Strategy and Market Position - The company’s AI strategy is entering a harvest phase, with innovative AI products contributing significantly to revenue and maintaining high gross margins [2] - Meinian Health leverages over 200 million structured health data points to enhance its AI product development, creating a closed loop of "data - algorithm - product" [2] - The company is positioned as a key player in personal health management, with a clear second growth curve supported by AI and innovative products [2]

Core Insights - Meinian Health (002044.SZ) reported a significant increase in net profit for Q3 2025, achieving a net profit of 273 million yuan, a year-on-year growth of 13.65% [1] - The company's net profit for the first three quarters reached 51.86 million yuan, marking a 110.53% increase compared to the previous year [1] - AI-driven revenue for the first three quarters amounted to approximately 250 million yuan, reflecting a 71.02% increase year-on-year [1] Financial Performance - The company experienced a robust financial performance with a notable increase in net profit and revenue driven by AI technology [1][2] - The third quarter saw a strong contribution from AI-related services, including cardiopulmonary screening and AI-MDT reports [1] - The overall revenue growth is supported by improved customer engagement and increased conversion rates in health check services [1] Strategic Initiatives - Meinian Health is focusing on a multi-faceted approach to revenue growth and cost reduction, emphasizing differentiated product offerings and exceptional service experiences [1] - The company aims to enhance its operational efficiency through scientific and precise cost-cutting measures [1] - The strategic implementation of AI products is expected to create a closed-loop system of data, algorithms, and products, driving future growth [2] Market Position - As a leading player in the "AI + health management" sector, Meinian Health is optimizing its customer structure and improving profitability [2] - The company is well-positioned to benefit from the upcoming peak season for health check-ups, with an expected increase in customer visits [2] - Meinian Health's extensive structured health data provides a competitive advantage in AI product development and iteration [2]

证券代码：002044 证券简称：美年健康 公告编号：2025-078 美年大健康产业控股股份有限公司 关于 2025 年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司 2025 年前三季度计提坏账准备合计为 5,542.77 万元。 注：以上数据如存在尾差，属于四舍五入所致。 二、本次计提资产减值准备合理性以及对公司的影响 本次计提资产减值准备符合《企业会计准则》和公司内部控制制度的相 关规定，遵循谨慎性、合理性原则，符合公司的实际情况，能够更真实、准 确地反映公司财务状况、资产价值及经营成果。 2025 年前三季度，公司计提各项资产减值准备合计 5,542.77 万元，减 1 因公司合并报表范围变化而产生的增加变动情况。 根据《企业会计准则》和美年大健康产业控股股份有限公司（以下简称"公 司"）会计政策的相关规定，公司基于谨慎性原则，对截至 2025 年 9 月 30 日的 各项资产进行判断以及减值测试，对可能发生资产减值损失的资产计提减值准备。 2025 年前三季度，公司计提各项资产减值准备合计 5,542.77 万 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-079 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 由不超过人民币 36,236.56 万元调整为不超过人民币 35,236.56 万元。本次担保事 项无需单独提交公司董事会或股东会审议。 三、被担保方基本情况 名称：天津滨海新区美欣门诊有限公司 成立日期：2016 年 6 月 1 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2024 年 12 月 13 日召开第九届董事会第五次（临时）会议及 2024 年 12 月 30 日召开 2024 年第六次临时股东大会，审议通过《关于公司及下属子公司申请融资额度并提供 担保的议案》，同意公司及部分下属子公司 2025 年度为公司及合并报表范围内的 子公司提供担保额度累计不超过人民币 49 亿元。具体内容详见公司于 2024 年 12 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司及下属子公司申请 融资额 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-076 美年大健康产业控股股份有限公司 第九届董事会第十五次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第十五 次（临时）会议于 2025 年 10 月 24 日以电子发送等形式发出会议通知，会议于 2025 年 10 月 30 日上午 10 时以通讯方式召开。应出席本次会议的董事为 9 名，实际出 席会议的董事为 9 名。会议由公司董事长俞熔先生主持，公司高级管理人员列席 了会议。本次会议的出席人数、召开表决程序、议事内容均符合《中华人民共和 国公司法》《公司章程》等有关规定。 二、董事会会议审议情况 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 公司董事会审计委员会审议通过了该议案。 《公司 2025 年第三季度报告》详见公司指定信息披露媒体《中国证券报》、《上 海证券报》、《证券时报》、《证券日报》及巨潮资讯网（www.cninfo.com.cn）。 三、备查文件 1、公司 ...

Core Insights - The company reported a third-quarter revenue of 2.816 billion yuan, representing a year-on-year decline of 4.06% [1] - The net profit for the third quarter was 273 million yuan, showing a year-on-year increase of 13.65% [1] - For the first three quarters, the total revenue was 6.925 billion yuan, down 3.01% year-on-year [1] - The net profit for the first three quarters reached 51.8599 million yuan, reflecting a significant year-on-year growth of 110.53% [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥2,816,138,023.06, a decrease of 4.06% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2025 reached ¥273,222,939.45, an increase of 13.65% year-on-year[3]. - The basic earnings per share for Q3 2025 was ¥0.07, reflecting a growth of 16.67% compared to the previous year[3]. - The company achieved a total revenue of 692,539.01 million RMB for the first three quarters, a decrease of 3.01% year-on-year[15]. - Net profit attributable to shareholders for the same period was 51,859.9 million RMB, an increase of 110.53% year-on-year[15]. - In Q3 alone, the company reported revenue of 281,613.80 million RMB, down 4.06% year-on-year, while net profit reached 27,322.29 million RMB, up 13.65% year-on-year[15]. - Total operating revenue for the current period was ¥6,925,390,135.63, a decrease of 3.01% from ¥7,140,540,911.69 in the previous period[52]. - Net profit for the current period was ¥91,460,115.74, an increase of 13.5% compared to ¥80,541,626.74 in the previous period[53]. - The total assets decreased from ¥20,126,714,816.93 to ¥19,567,663,818.73, reflecting a decline of 2.78%[50]. - Total liabilities decreased to ¥10,843,480,221.19, down from ¥11,423,788,765.09, a reduction of 5.06%[50]. Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥181,868,438.48 for the year-to-date, representing a 40.03% increase in outflow compared to the previous year[3]. - The cash flow statement indicates a stable cash position, with no significant changes reported[55]. - Operating cash flow net amount was -181,868,438.48, an improvement from -303,249,875.96 in the previous period, indicating a reduction in cash outflow[57]. - Total cash inflow from operating activities was 5,897,684,855.45, slightly up from 5,874,172,164.72 in the previous period[56]. - Cash outflow from operating activities totaled 6,181,344,471.16, down from 6,271,453,561.73 in the previous period[57]. - The ending cash and cash equivalents balance was 1,873,055,412.03, up from 1,458,322,274.51 in the previous period[58]. - As of September 30, 2025, the company's total current assets amounted to CNY 6,517,530,486.47, a decrease of 4.54% from CNY 6,827,461,321.14 at the beginning of the period[49]. - The cash and cash equivalents decreased to CNY 2,010,659,401.94 from CNY 3,069,635,444.40, representing a decline of 34.5%[49]. - The company's non-current assets totaled CNY 13,050,133,332.26, a slight decrease of 1.87% from CNY 13,299,253,495.79[49]. Investments and Acquisitions - The company approved a plan to acquire equity stakes in 11 companies, including Hengyang Meinian Health Examination Center Co., Ltd., through a share issuance[45]. - The company is awaiting approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission for its asset acquisition plan, which carries uncertainties regarding the timing and outcome[46]. Research and Development - The company reported a substantial increase in development expenditures, which rose by 357.78% to ¥54,193,066.36, attributed to ongoing capitalized R&D projects[9]. - Research and development expenses were ¥36,848,699.31, a slight decrease from ¥37,492,770.55[52]. Customer Engagement and Services - The company operates 561 branches, with 300 being controlled branches, and is focusing on enhancing customer management and conversion rates[14]. - The AI-driven personalized health check package recommendation has been launched across 167 cities, improving service efficiency[17]. - The company has implemented a full AI quality control system for ultrasound services, enhancing the examination experience[19]. - The company is expanding its product offerings, including traditional and innovative health management solutions, to create a comprehensive service loop[18]. - The company launched the "Health Management After Check-up" service, which is gradually becoming a new growth point for its business[21]. Community and Social Responsibility - The company is committed to social responsibility, focusing on health care for vulnerable groups through various public welfare initiatives[23]. - The company has initiated a public welfare project focusing on early screening for brain health among the elderly, aiming to safeguard national health through professional medical capabilities[22]. - The company is actively involved in community health education, conducting health knowledge dissemination activities in local communities, with nearly 100 residents receiving free health checks and consultations[33]. - A health lecture was organized for employees of a local manufacturing company, addressing common occupational health issues and promoting a scientific health concept of early prevention and treatment[35]. - The company is building a sustainable public welfare ecosystem through innovative activities like the "Charity Run," which attracted over 800 participants[37]. Technology and Innovation - Revenue generated from AI technology applications amounted to 24,963.84 million RMB, reflecting a growth of 71.02% compared to the previous year[15]. - The company is focusing on enhancing the value of medical data assets and exploring innovative applications, leveraging big data in health check-ups and deepening the application of digital and AI technologies in health management[20]. - The AI chronic disease management product matrix is taking shape, with key products like "Lung Health" and "Brain Health" being continuously upgraded and promoted across over 30 regions, marking a new growth point for the company[21]. - The company is collaborating with Huawei to advance an AI smart wearable project, aiming to create a closed-loop health management service[20].

Core Viewpoint - The stock of Meinian Health has reached a new high in trading volume, indicating strong market interest and performance [1] Group 1: Company Performance - As of 11:24 AM, Meinian Health's trading volume reached 1.535 billion RMB, marking the highest level since March 11, 2025 [1] - The latest stock price increased by 9.73%, with a turnover rate of 7.09% [1] - The previous trading day saw a total trading volume of 279 million RMB [1] Group 2: Company Background - Meinian Health Industry Holdings Co., Ltd. was established on January 22, 1991, with a registered capital of 3.91425 billion RMB [1]